HER2‐expressing PDX models were subjected to combined trastuzumab deruxtecan (T‐DXd) and adavosertib therapy regimens, followed by evaluation of tumor growth through immunohistochemistry and reverse‐phase protein array analysis.161. This evidence concerns the gene ERBB2 and neoplasm.